Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo- O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2891-2894

  Berg, Stacey L ^a,c   Murry, Daryl J ^a   McCully, Cindy L ^b   Godwin, Karen ^b   Balis, Frank M ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; 8 OXO 6 O BENZYLGUANINE; ALKYLATING AGENT; ALKYLGUANINE ALKYLTRANSFERASE; CARMUSTINE; DRUG METABOLITE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; TRANSFERASE; UNCLASSIFIED DRUG; 8 OXO O(6) BENZYLGUANINE; 8-OXO-O(6)-BENZYLGUANINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GUANINE; O(6) BENZYLGUANINE; O(6)-BENZYLGUANINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRATHECAL DRUG ADMINISTRATION; LATERAL BRAIN VENTRICLE; MALE; MENINGIOMA; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; ANIMAL; INTRASPINAL DRUG ADMINISTRATION; MACACA; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; GUANINE; INJECTIONS, SPINAL; MACACA MULATTA; MALE;

EID: 0031593375     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. 6-alkylguanine. FASEB J., 6: 2302-2310, 1992.
2. 6-benzylguanine. Biochemistry, 32: 11998-2006, 1993.
3. 6-alkylguanine DNA alkyltransferase. Proc. Am. Assoc. Cancer Res., 35: 699-700, 1994.
4. 6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro. Cancer Res., 53: 4281-4286, 1993.
5. 6-benzylguanine in vitro and in vivo. Anticancer Res., 13: 801-805, 1993.
6. Friedinan, H. S., Dolan, M. E., Moschel, R. C. Pegg, A. E., Felker, G. M., Rich, J., Bigner, D. D., and Schold, S. J. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J. Natl. Cancer Inst., 84: 1926-1931, 1992.
7. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem. Pharmacol., 45: 483-491, 1993.
8. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res., 51: 3367-3372, 1991.
9. 6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. Cancer Res., 55: 4606-4610, 1995.
10. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol., 32: 471-476, 1993.
11. 6-alkyltransferase activity based on cellular DNA content in human, rat, and mouse tissues. Carcinogensis (Lond.), 7: 745-749, 1986.
12. 6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood, 89: 1566-1573, 1997.
13. National Research Council. Guide for the care and use of laboratory animals. Washington, D. C.: National Academy Press, 1996.
14. McCully, C., Balis, F., Bacher, J., Phillips, J., and Poplack, D. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab. Animal Sci., 40: 522-525, 1990.
15. 6-methylguanine-DNA alklytransferase inhibitor. Proc. Am. Assoc. Cancer Res., 33: 534, 1992.
16. D'Argenio, D. Z., and Schumitzky, A. ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, pp. 115-134. Los Angeles: University of Southern California, 1997.
17. 6-benzylguanine. Proc. Am. Assoc. Cancer Res., 36: A846, 1995.
18. Bendotti, C., Prosperini, E., Kurosaki, M., Garattini, E., and Terao, M. Selective localization of mouse aldehyde oxidase mRNA in the choroid plexus and motor neurons. Neuroreport, 8: 2343-2349, 1997.
19. 6-alkylguanine-DNA alkyltransferase. Cancer Res., 54: 5123-5130, 1994.
20. DeVita, V., Denham, C., Davidson, J., and Oliverio, V. The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyl)-nitrosourea (BCNU) in man and animals. Clin. Pharmacol. Ther., 8: 566-577, 1967.
21. Patel, M., McCully, C., Godwin, K., and Balis, F. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc. Am. Soc. Clin. Oncol., 14: A1485, 1995.